Active ingredient
Retatrutide: FDA Status, Uses, Safety and Cost
Three receptor targets (GIP + GLP-1 + glucagon)
Not FDA approved
Retatrutide is an investigational compound. It has not been approved by the FDA for any use, its safety and effectiveness have not been established, and it cannot legally be sold or dispensed as a medication in the United States. There is no legitimate way to purchase it. This page is informational only.
What Retatrutide is
Retatrutide is an investigational medication being developed by Eli Lilly that targets three hormone receptors — GIP, GLP-1, and glucagon. It is NOT FDA approved for any use. It is being studied in clinical trials for obesity and related conditions; there is no approved product, no official prescribing information, and no legitimate way to buy it outside a clinical trial.
Key facts
| Generic (active ingredient) | Retatrutide |
|---|---|
| Brand names | None — investigational compound |
| Drug class | Triple GIP, GLP-1, and glucagon receptor agonist |
| Manufacturer | Eli Lilly and Company (developer) |
| FDA status | InvestigationalNot FDA approved |
| Administration | Subcutaneous injection (in clinical trials) |
| Frequency | Once weekly (in clinical trials) |
| Approval date | Not applicable — not FDA approved |
| Prescription required | Yes |
| Official label | None — no approved product exists |
What Retatrutide is approved for
None. Retatrutide has no FDA-approved indications because it is not an approved drug. Claims that it is approved, or that it can be legally prescribed or sold, are false.
How Retatrutide works
Retatrutide is designed to activate GIP, GLP-1, and glucagon receptors simultaneously. Because it is investigational, its efficacy and safety have not been established by the FDA, and any published results come from ongoing clinical research.
Administration
Retatrutide is given by subcutaneous injection (in clinical trials), once weekly (in clinical trials).
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
There is no FDA-approved labeling for Retatrutide, so there is no established list of warnings, contraindications, or adverse reactions. Absence of a warning here does not mean the compound is safe — it means safety has not been established.
Cost and access
- Not available by prescription — it is not an approved drug.
- Products sold online as "retatrutide" are unapproved and potentially dangerous; no licensed U.S. pharmacy can legally dispense it.
- The only legitimate access is enrollment in a registered clinical trial (see ClinicalTrials.gov).
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Not applicable — investigational drugs are not covered products.
More detail: how insurance coverage works for weight-loss medication.
Frequently asked questions
- Is retatrutide FDA approved?
- No. Retatrutide is investigational and not FDA approved for any use. Its safety and effectiveness have not been established by the FDA.
- Can I buy retatrutide online?
- No legitimate seller exists. Anything sold online as retatrutide is an unapproved product of unknown identity, purity, and safety. We do not link to or endorse any source for investigational compounds.
Related guides
Sources
- ClinicalTrials.gov — retatrutide studies — NIH. Link last verified August 12, 2026.
- FDA: concerns with unapproved GLP-1 drugs — FDA. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.